ストックスクリーナーアプリを入手
1.39
0.72%
0.01
前日終値:
$1.38
開ける：
$1.41
24時間の取引高:
17,589
Relative Volume:
0.44
時価総額：
$68.42M
収益：
$409.70K
当期純損益:
$-12.00M
株価収益率:
-5.6851
EPS:
-0.2445
ネットキャッシュフロー:
$-9.81M
1週間 パフォーマンス:
-2.80%
1か月 パフォーマンス:
+9.45%
6か月 パフォーマンス:
-8.55%
1年 パフォーマンス:
+9.45%
1日の値動き範囲:
$1.38
$1.41
1週間の範囲:
$1.38
$1.49
52週間の値動き範囲:
$1.168
$1.96
Medicinova Inc Stock (MNOV) Company Profile
Compare MNOV vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MNOV
Medicinova Inc
|
1.39 | 68.42M | 409.70K | -12.00M | -9.81M | -0.2445 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Medicinova Inc Stock (MNOV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-16 | 開始されました | H.C. Wainwright | Buy |
| 2021-03-10 | 開始されました | Maxim Group | Buy |
| 2019-03-25 | 再開されました | B. Riley FBR | Buy |
| 2018-03-28 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2017-04-18 | 開始されました | Credit Suisse | Outperform |
| 2013-01-04 | 繰り返されました | Ladenburg Thalmann | Buy |
| 2012-05-24 | ダウングレード | MLV & Co | Buy → Hold |
| 2011-10-18 | 繰り返されました | MLV Capital | Buy |
| 2011-06-22 | 開始されました | Global Hunter Securities | Buy |
| 2010-05-12 | 開始されました | Wedbush | Outperform |
| 2008-11-12 | 繰り返されました | Ladenburg Thalmann | Buy |
| 2008-05-15 | 開始されました | Rodman & Renshaw | Mkt Outperform |
| 2007-07-09 | 開始されました | Punk, Ziegel & Co | Buy |
すべてを表示
Medicinova Inc (MNOV) 最新ニュース
D Boral Capital maintains MediciNova (MNOV) buy recommendation - MSN
MediciNova Inc outlines its biotech pipeline as investors watch MN-166 progress - ad-hoc-news.de
Medicinova Inc (MNOV) Holds Steady Near Support After Modest AdvanceFactor Crowding - dars.gov.et
Medicinova Inc (MNOV) Surges 7.6% as Biotech Stock Tests Resistance at $1.49Opening Range Breakout - dars.gov.et
Enterprise value to revenue forward of MediciNova, Inc. – TSE:4875 - TradingView
Price to earnings forward of MediciNova, Inc. – TSE:4875 - TradingView
Enterprise value to EBITDA forward of MediciNova, Inc. – NASDAQ:MNOV - TradingView
MediciNova completes patient visits in phase 2 NAFLD trial - Investing.com
MediciNova CEO Provides Shareholder Update - GlobeNewswire
Medicinova Inc (MNOV) Edges Higher: Biotech Stock Tests Resistance After Modest GainPrice Target - dars.gov.et
MediciNova Inc (MNOV) Valuation: PE, PB & Fair Value Analysis - TradingKey
MediciNova, Inc. Actuals & Estimates (NASDAQ:MNOV) - TradingView
Form 4 MediciNova Inc For: 25 June By Investing.com - Investing.com Nigeria
MediciNova (MNOV) director awarded 44,500 stock options - Stock Titan
MediciNova (MNOV) director Nicole Lemerond receives 44,500 stock options grant - Stock Titan
MediciNova (MNOV) director receives grant of 44,500 stock options - Stock Titan
MediciNova Shareholders Reject Proposal to Increase Authorized Stock - TipRanks
MediciNova (MNOV) 2026 annual meeting voting recap and totals - Stock Titan
MediciNova Inc (MNOV) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
MediciNova Inc (MNOV) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
MediciNova Inc (MNOV) Institutional Confidence - TradingKey
MediciNova Inc (MNOV) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
MediciNova Inc (MNOV) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
MediciNova Inc (MNOV) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
MediciNova Inc (MNOV) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
MediciNova: Interview With Founder And CEO Dr. Yuichi Iwaki About The Biotech - Pulse 2.0
MNOV Q1 2026 Earnings: Narrower Loss Beats Estimates as Clinical Pipeline AdvancesEBITDA Estimate Trend - newsline.com
MNOV Q1 2026 Earnings: Narrower Loss Beats Estimates but Stock Slides on No Revenue UpdateFiscal Year Earnings - dars.gov.et
MNOV Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineEarnings Risk Report - dars.gov.et
Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsight - GlobeNewswire Inc.
MediciNova receives U.S. patent allowance for ibudilast combo By Investing.com - Investing.com South Africa
MediciNova receives U.S. patent allowance for ibudilast combo - Investing.com India
MediciNova Receives Notice of Allowance for New Patent - GlobeNewswire
MediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatment - Yahoo Finance
Medicinova Inc (MNOV) Holds Steady, Consolidating Around the $1.31 MarkCovered Call ETF - newsline.com
MediciNova Inc stock (US58468P2038): Nasdaq biotech share edges higher while valuation metrics stay subdued - AD HOC NEWS
MNOV Q1 2026 Earnings: Narrower Loss Beats Estimates as Pipeline AdvancesFinancial Health Score - newsline.com
MediciNova, Inc. Financial Disclosures & SEC Filings - TradingView
MNOV Q1 2026 Earnings: Narrower-Than-Expected Loss as Clinical Pipeline AdvancesPreliminary Results - newsline.com
MNOV Q1 2026 Earnings: EPS Surpasses Estimates with Narrower Loss; No Revenue ReportedEarnings Season Preview - The Legal Advocate
MNOV Q1 2026 Earnings: Narrower-than-Expected Loss Reported, Shares DipEarnings Beat Alert - The Legal Advocate
MNOV Q1 2026 Earnings: EPS Beat Against Estimates, Cash Burn Concerns Weigh on SharesAnnual Earnings Summary - The Legal Advocate
MediciNova Inc stock (US58468P2038): valuation snapshot as biotech progresses MN-001 trial milestone - AD HOC NEWS
H.C. Wainwright Maintains MediciNova(MNOV.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Maxim Group Maintains MediciNova(MNOV.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Medicinova (MNOV) Slides 4% as Stock Tests Key Support Near $1.24Cup and Handle - The Legal Advocate
MediciNova Completes MN-001-NATG-202 Clinical Trial Evaluating Tipelukast - geneonline.com
MNOVMedicinova Inc Stock Price and Quote - Finviz
MediciNova, Inc. Announces Completion of Last Patient Visit in Phase 2 Trial of MN-001 for Hypertriglyceridemia and NAFLD Associated with Type 2 Diabetes - Quiver Quantitative
Fatty liver, high triglyceride diabetes trial hits final patient visit - Stock Titan
MediciNova Announces Completion of Last Patient Last Visit - GlobeNewswire
Medicinova Inc (MNOV) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):